2025 年製药和生技领域的六大成长机会

Top 6 Growth Opportunities in Pharma-Biotech, 2025

出版日期: 2025年02月20日 | 出版商:

Frost & Sullivan | 英文 12 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录

2025年，製药和生技产业正进入一个由科学创新、不断变化的法规和市场压力融合所塑造的转型时代。其中一个关键挑战是治疗学和药物核准的持续推进，尤其是个人化医疗的突破性治疗有望彻底改变患者护理。肿瘤学仍将是价值最高的治疗领域，免疫调节剂将透过现有重磅药物的销售实现成长，肥胖症和中枢神经系统将产生新一轮增长。然而，随着新治疗方法的出现，政府和保险公司寻求更具成本效益的解决方案并推动製药公司提供更多价值，定价压力正在加剧。

作为回应，製造商正在优化生产流程，更加重视高效外包，并引入新的製造技术以满足不断增长的全球需求，同时保持成本效益。同时，数位技术和人工智慧（AI）将加速研发、简化药物发现、优化临床试验和个人化治疗途径。这些技术进步对于克服药物开发的复杂挑战尤其重要。

此外，新兴市场正成为成长的焦点。随着亚洲、中东和拉丁美洲等地区人口不断增长，製药公司正在抓住机会进入这些充满活力的市场，并利用独特的监管和经济状况为服务不足的患者群体提供创新的解决方案。这些战略要务的融合正在重塑2025年製药和生技产业的未来。

本报告研究了全球製药和生物技术市场，并提供了市场概况、策略要务和成长机会。

策略要务
六大成长机会
成长机会1：放射配体治疗促进精准肿瘤学发展
成长机会2：抗体疗法彻底改变免疫学和炎症
成长机会三：医药市场利用 IT 解决方案提高价格透明度
成长机会#4：医疗副驾驶为临床试验服务赋能
成长机会5：亚太地区 CDMO 在製造业格局变化中扩大规模
成长机会#6：透过策略伙伴关係神经保护疗法的发展
免责声明

简介目录

Product Code: PFR2-52

Unlocking Growth in Precision Therapeutics, Digital Innovation, Manufacturing, and Emerging Markets

The pharmaceutical and biotechnology industries are entering a transformative era in 2025, shaped by a convergence of scientific innovation, regulatory evolution, and market pressures. One of the key imperatives is the continued advancement of therapeutics and drug approvals, as breakthrough treatments, particularly in personalized medicine, promise to revolutionize patient care. Oncology will remain the most valuable therapy area, while the immunomodulator segment will grow through existing blockbuster sales, and obesity and CNS will create fresh waves of growth rates. However, as new therapies emerge, drug pricing pressures are intensifying, with governments and insurers pushing for more cost-effective solutions, demanding greater value from pharmaceutical companies.

In response, manufacturers are optimizing production processes, increasing focus on efficient outsourcing, and embracing new manufacturing technologies to meet growing global demand while maintaining cost efficiency. At the same time, digital technologies and artificial intelligence (AI) are poised to accelerate R&D, streamlining drug discovery, optimizing clinical trials, and personalizing treatment pathways. These technological advancements are particularly pivotal in overcoming the complex challenges in pharmaceutical development.

Furthermore, emerging markets are becoming a central focus for growth. As populations in regions such as Asia, the Middle East, and Latin America continue to expand, pharmaceutical companies are seizing opportunities to tap into these dynamic markets, navigating unique regulatory and economic landscapes to deliver innovative solutions to underserved patient populations. These strategic imperatives' convergence is reshaping the future of the pharmaceutical and biotechnology industries in 2025.

Top Growth Opportunities for 2025

Strategic Imperatives
Top 6 Growth Opportunities
Growth Opportunity 1: Radioligand Therapeutics is Fueling Precision Oncology
Growth Opportunity 2: Antibody Therapies are Revolutionizing Immunology and Inflammation
Growth Opportunity 3: The Pharmaceutical Market is Accessing IT Solutions to Ensure Higher Price Transparency
Growth Opportunity 4: Medical Co-pilots are Empowering Clinical Trial Peripheral Services
Growth Opportunity 5: APAC CDMOs are Scaling up Amid the Shifting Manufacturing Landscape
Growth Opportunity 6: Neuroprotective Therapy is Advancing Through Strategic Partnerships
Legal Disclaimer

02-2729-4219

+886-2-2729-4219